Bausch + Lomb FY2024 EPS Estimate Lowered by HC Wainwright

Bausch + Lomb Co. (NYSE:BLCO) – HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Bausch + Lomb in a research note issued on Thursday, October 31st. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.60 per share for the year, down from their previous estimate of $0.61. HC Wainwright has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.59 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q4 2024 earnings at $0.27 EPS, Q1 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.28 EPS and FY2025 earnings at $0.94 EPS.

Other analysts also recently issued reports about the stock. Stifel Nicolaus increased their price target on shares of Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research report on Monday, September 23rd. Evercore increased their target price on Bausch + Lomb from $15.50 to $17.00 and gave the stock an “in-line” rating in a report on Thursday, August 1st. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Citigroup boosted their target price on shares of Bausch + Lomb from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Raymond James started coverage on Bausch + Lomb in a report on Wednesday, July 10th. They set an “outperform” rating and a $19.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.91.

Bausch + Lomb Trading Down 0.3 %

NYSE:BLCO opened at $19.81 on Monday. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of -18.87, a PEG ratio of 1.93 and a beta of 0.46. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The business’s 50-day moving average price is $18.68 and its two-hundred day moving average price is $16.52. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.01. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. Bausch + Lomb’s revenue was up 18.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.22 earnings per share.

Institutional Trading of Bausch + Lomb

Institutional investors and hedge funds have recently modified their holdings of the business. Point72 Europe London LLP boosted its position in Bausch + Lomb by 28.9% during the 2nd quarter. Point72 Europe London LLP now owns 653,492 shares of the company’s stock worth $9,489,000 after buying an additional 146,583 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Bausch + Lomb in the 2nd quarter worth about $580,000. Clearline Capital LP increased its stake in shares of Bausch + Lomb by 136.8% in the 2nd quarter. Clearline Capital LP now owns 712,055 shares of the company’s stock valued at $10,339,000 after acquiring an additional 411,404 shares in the last quarter. Gabelli Funds LLC boosted its holdings in Bausch + Lomb by 25.0% in the second quarter. Gabelli Funds LLC now owns 390,000 shares of the company’s stock worth $5,663,000 after acquiring an additional 78,000 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Bausch + Lomb during the second quarter valued at about $1,911,000. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.